Previous 10 | Next 10 |
Healthcare stocks in the S&P 500 edged past the ~0.6% loss in the broader index over the week to end ~0.2% lower, becoming the fourth best performing sector. Among stocks with more than $300M market cap and over 100K average daily volume over the past five sessions, BELLUS Health (NA...
Commodity prices have played a significant role on Wall Street this week -- a trend that continued Thursday as a drop in gold sparked a slide in mining stocks. Newmont (NYSE:NEM), Barrick Gold (NYSE:GOLD), Kinross Gold (NYSE:KGC) and Agnico Eagle Mines (NYSE:AEM) all staged notable retreats. ...
Gainers: Offerpad Solutions (NYSE:OPAD) +48%. Arqit Quantum (NASDAQ:ARQQ) +36%. AEye (NASDAQ:LIDR) +36%. Rockley (NYSE:RKLY) +29%. IronNet (NYSE:IRNT) +32%. Leap Therapeutics (NASDAQ:LPTX) +27%. aTyr Pharma (NASDAQ:LIFE) +27%. Tuesday Morning Corporation (NASDAQ:TUEM) ...
– Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechani...
Gainers: Communications Systems (NASDAQ:JCS) +33%. BELLUS Health (NASDAQ:BLU) +20%. Matinas BioPharma (NYSE:MTNB) +19%. Onion Global (NYSE:OG) +18%. FuelCell Energy (NASDAQ:FCEL) +17%. Silverback Therapeutics (NASDAQ:SBTX) +16%. DatChat (NASDAQ:DATS) +15%. Calumet (NASDAQ:CLMT) +15%. Ada...
Gainers: Itamar (NASDAQ:ITMR) +46%. Aterian (NASDAQ:ATER) +40%. aTyr Pharma (NASDAQ:LIFE) +37%. iRhythm Technology (NASDAQ:IRTC) +34%. BELLUS (NASDAQ:BLU) +26%. Leap Therapeutics (NASDAQ:LPTX) +30%. REGENXBIO (NASDAQ:RGNX) +25%. Datasea (NASDAQ:DTSS) +20%. Uranium Royalty (NASDAQ:UROY) ...
Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...
– Interim monotherapy and initial pembrolizumab combination data from the dose-escalation arm of the SBT6050-101 trial will be reported – – Conference call to be held on Thursday, September 16, 2021, at 6:30 AM ET – Silverback Therapeutics...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
A group of small biotech companies are warning President Biden, Rep. Nancy Pelosi (D-Calif.), Sen. Chuck Schumer (D.-N.Y.) and other top lawmakers about the negative effects a proposed drug pricing bill would have on their industry. In a letter, they say that government-dictated prices for dr...
News, Short Squeeze, Breakout and More Instantly...
Silverback Therapeutics Inc. Company Name:
SBTX Stock Symbol:
NASDAQ Market:
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated ...
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA Guidance Submission...
Preparing to submit response to the FDA’s CRL for neffy ® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with ...